<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909831</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000643294</org_study_id>
    <secondary_id>UPCC-08908</secondary_id>
    <secondary_id>807931</secondary_id>
    <secondary_id>WYETH-C-UPCC-03809</secondary_id>
    <nct_id>NCT00909831</nct_id>
  </id_info>
  <brief_title>Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment</brief_title>
  <official_title>A Phase I Trial of Hydroxychloroquine in Combination With Temsirolimus in Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as hydroxychloroquine, work in different ways to&#xD;
      stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes&#xD;
      needed for cell growth. Giving hydroxychloroquine together with temsirolimus may kill more&#xD;
      tumor cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of hydroxychloroquine&#xD;
      when given together with temsirolimus in treating patients with metastatic solid tumors that&#xD;
      have not responded to treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of hydroxychloroquine (HCQ) in combination with&#xD;
           temsirolimus (TEM) in patients with metastatic refractory solid tumors.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Describe the toxicity of this regimen in these patients.&#xD;
&#xD;
        -  Measure the response rate in patients treated with this regimen.&#xD;
&#xD;
      Tertiary&#xD;
&#xD;
        -  Establish a population pharmacokinetic (PK) model for HCQ and its metabolites in&#xD;
           combination with TEM.&#xD;
&#xD;
        -  Use the population PK model to estimate the exposure of HCQ in individual patients.&#xD;
&#xD;
        -  Compare PK parameters for this regimen to data from published single agent studies.&#xD;
&#xD;
        -  Measure the change in median number of autophagic vesicles/cell in peripheral blood&#xD;
           mononuclear cells with TEM alone and with TEM and HCQ and correlate these changes with&#xD;
           HCQ exposure.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of hydroxychloroquine.&#xD;
&#xD;
      Patients receive temsirolimus IV over 30 minutes once a week beginning in week 1 and oral&#xD;
      hydroxychloroquine twice daily beginning in week 2. Courses repeat every 8 weeks in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Blood samples are collected at baseline and periodically during study for pharmacokinetic and&#xD;
      pharmacodynamic studies and measurement of autophagy inhibition. Samples are analyzed via&#xD;
      HPLC and tandem mass spectrometry, immunoblotting assays, and electron microscopy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of hydroxychloroquine</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity rate as assessed by NCI CTCAE v. 3.0</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic and pharmacodynamic correlative endpoints</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hydroxychloroquine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>temsirolimus</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electron microscopy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>high performance liquid chromatography</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunologic technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>mass spectrometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>autophagy inhibition therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed refractory solid tumor for which no curative standard therapy&#xD;
             exists&#xD;
&#xD;
               -  Metastatic disease&#xD;
&#xD;
          -  Treated brain metastases that have been stable ≥ 3 months allowed&#xD;
&#xD;
               -  At least 1 week since prior steroids&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status of 0-1&#xD;
&#xD;
          -  ANC ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine ≤ 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT and AST ≤ 5 times ULN&#xD;
&#xD;
          -  Total bilirubin ≤ 1.5 mg/dL&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No serious concurrent infection or medical illness that would jeopardize the ability&#xD;
             of the patient to receive the treatment outlined in this protocol with reasonable&#xD;
             safety&#xD;
&#xD;
          -  No prior or other concurrent malignancy except for curatively treated&#xD;
             carcinoma-in-situ at any site or basal cell carcinoma or squamous cell carcinoma of&#xD;
             the skin&#xD;
&#xD;
               -  Patients who have been free of disease (any prior malignancy) for ≥ 5 years are&#xD;
                  eligible&#xD;
&#xD;
          -  No porphyria&#xD;
&#xD;
          -  No psoriasis, except well controlled psoriasis under the care of a specialist&#xD;
&#xD;
          -  No previously documented macular degeneration or diabetic retinopathy&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Any number and type of prior anticancer therapies allowed&#xD;
&#xD;
          -  No prior mTOR inhibitors&#xD;
&#xD;
          -  At least 4 weeks since prior immunotherapy (i.e., aldesleukin, interferon, CTLA-4) or&#xD;
             chemotherapy and recovered&#xD;
&#xD;
          -  At least 2 weeks since prior oral targeted therapy and recovered&#xD;
&#xD;
          -  At least 4 weeks since prior and no other concurrent investigational anticancer&#xD;
             therapy (except for vaccines)&#xD;
&#xD;
          -  No other concurrent therapy&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent cytochrome P450 enzyme-inducing anticonvulsant drugs (i.e., phenytoin,&#xD;
             carbamazepine, phenobarbital, primidone, or oxcarbazepine)&#xD;
&#xD;
          -  Concurrent non-enzyme inducing anticonvulsants, including felbamate, valproic acid,&#xD;
             gabapentin, lamotrigine, tiagabine, topiramate, zonisamide, or levetiracetam allowed&#xD;
&#xD;
          -  Concurrent hematologic growth factors (filgrastim [G-CSF], pegfilgrastim, epoetin&#xD;
             alfa) allowed in patients with severe myelosuppression&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Amaravadi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104-4283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 28, 2009</study_first_submitted>
  <study_first_submitted_qc>May 28, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2009</study_first_posted>
  <last_update_submitted>April 12, 2019</last_update_submitted>
  <last_update_submitted_qc>April 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

